Fonseca Biosciences is redefining pharmaceutical commercialization for a new era. We collaborate with innovators who develop life-changing therapies, offering a bold approach to commercialization. Unlike conventional models, we invest our own resources to bring these products to market, ensuring faster rollout and greater impact.
We specialize in commercialization, a pivotal stage of the healthcare product lifecycle, leveraging laser-focused expertise and a proven process. Our visionary playbook enables us to take on all the risks of launching new therapies, delivering results with unmatched speed and precision.
At Fonseca, we seek out game-changing products that address unmet needs—solutions that help people live healthier, happier lives. When we find the right match, we bring it to market with unparalleled efficiency, creating a win-win for patients and partners alike.
This way, everybody wins.
Now Approved
XTORO® for acute otitis externa
XTORO® (finafloxacin otic suspension) 0.3% is an FDA-approved quinolone antimicrobial for the treatment of acute otitis externa, commonly known as swimmer’s ear.
See Full Prescribing Information Learn more at XTORO.us